Capstone Therapeutics
1275 West Washington
Tempe
Arizona
85281
United States
Tel: 602-286-5520
Website: http://www.capstonethx.com/
81 articles about Capstone Therapeutics
-
Capstone Therapeutics Corp. Announces Results Of Annual Meeting - March 07, 2023
3/7/2023
The Annual Meeting of Stockholders of Capstone Therapeutics Corp., a Delaware corporation, was held on Thursday, March 2, 2023, by request of the majority shareholder, for the following purposes.
-
Capstone Therapeutics Corp. Announces Transaction with Diamond Products Holdings, LLC
4/6/2021
On March 31, 2021, the Company, through its relationship with Brookstone Partners, executed definitive documents and acquired a minority interest in a consumer products company, Diamond Products, LLC, a sexual wellness holding company.
-
Capstone Therapeutics Announces Exercise of Secured Debt and Interest Conversion Option by BP Peptides, LLC and Change in Control
12/28/2020
Capstone Therapeutics (OTCQB:CAPS) EXERCISE OF SECURED DEBT AND INTEREST CONVERSION OPTION; ISSUANCE OF 24,900 SHARES OF THE COMPANYS COMMON STOCK On December 21, 2020, BP Peptides, LLC exercised its right to convert $572,700 of accrued interest and secured debt into 24,900 shares of the Companys Common Stock (exercise price of $23/share).
-
CAPSTONE THERAPEUTICS ANNOUNCES TRANSACTION WITH TOTALSTONE LLC
3/28/2020
Capstone Therapeutics (OTCQB: CAPS) (“the Company”) RECAPITALIZATION OF AND MERGER WITH TOTALSTONE LLC In March 2020, the Company entered into an agreement, which will be effective April 1, 2020, to obtain an interest in materials distribution company (TotalStone, LLC), which distributes masonry stone products for residential and commercial construction in the Midwest and Northeast United States under the trade names Instone and Northeast
-
Capstone Therapeutics Announces Transaction For Sale Of Shares Of Its Common Stock And Secured Loan
7/17/2017
-
Capstone Therapeutics Announces Existing Shareholder Decision Not To Extend Exclusive Due Diligence Period
2/4/2016
-
Capstone Therapeutics Announces Allowance Of U.S. Patent For Treatment Of Diabetes With Apo E Mimetic Peptides
10/14/2015
-
Capstone Therapeutics Announces Patent Application For Novel, More Potent Chimeric Apo E Mimetic Peptides
7/23/2015
-
Capstone Therapeutics Announces Settlement Of Qui Tam Lawsuit
6/2/2015
-
Capstone Therapeutics Announces First Quarter 2015 Financial Results and Operating Update Conference Call
5/22/2015
-
Capstone Therapeutics Announces Operating Update Conference Call
3/23/2015
-
Capstone Therapeutics Announces Phase 1b/2a Study Results For AEM-28 Showing Safety And Biomarker Efficacy Signals
12/16/2014
-
Capstone Therapeutics Will Provide An Operating Update And Announces Third Quarter 2014 Financial Results
11/14/2014
-
Capstone Therapeutics Announces Third Quarter 2014 Financial Results And Operating Update Conference Call
11/6/2014
-
Capstone Therapeutics Announces Digital Corporate Communication Channels
9/8/2014
-
Capstone Therapeutics Announces Phase 1a Results For AEM-28 Showing Safety And Biomarker Efficacy Signals
9/2/2014
-
Capstone Therapeutics Will Provide An Operating Update And Announces Second Quarter 2014 Financial Results
8/14/2014
-
Capstone Therapeutics Announces Second Quarter 2014 Financial Results And Operating Update Conference Call
8/6/2014
-
Capstone Therapeutics Announces Initiation Of Dosing For AEM-28 Phase 1b/2a Human Clinical Trial In Refractory Hypercholesterolemic Subjects
6/12/2014
-
Capstone Therapeutics Announces Initiation Of Dosing For AEM-28 Phase 1b/2a Human Clinical Trial In Refractory Hypercholesterolemic Subjects
6/11/2014